Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study in Subjects Using Levemir (Insulin Detemir), NovoMix 30 (Biphasic Insulin Aspart 30) [insulin aspart/insulin protamine aspart] and/or NovoRapid (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus.

Trial Profile

Efficacy and Safety Study in Subjects Using Levemir (Insulin Detemir), NovoMix 30 (Biphasic Insulin Aspart 30) [insulin aspart/insulin protamine aspart] and/or NovoRapid (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Jul 2012 Additional locations added as reported by ClinicalTrials.gov.
    • 23 Oct 2009 Actual initiation date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
    • 14 Oct 2009 Actual patient number (5926) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top